One-year exenatide treatment improves beta cell response in metformin treated patients with type 2 diabetes which is sustained after 5 weeks discontinuation of treatment

被引：0

作者：

Bunck, M. C. ^{[1
]}

Mari, A. ^{[2
]}

Corner, A. ^{[3
]}

Eliasson, B. ^{[4
]}

Shaginian, R. M. ^{[5
]}

Wu, Y. ^{[6
]}

Yan, P. ^{[6
]}

Heine, R. J. ^{[1
,7
]}

Smith, U. ^{[4
]}

Taskinen, M. -R. ^{[3
]}

Yki-Jarvinen, H. ^{[3
]}

Diamant, M. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, Ctr Diabet, Amsterdam, Netherlands

[2] Inst Biomed Engn, Padua, Italy

[3] Univ Helsinki, Cent Hosp, Dept Med, FIN-00014 Helsinki, Finland

[4] Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, S-41345 Gothenburg, Sweden

[5] Eli Lilly & Co, Houten, Netherlands

[6] Amylin Pharmaceut Inc, San Diego, CA USA

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

DIABETOLOGIA | 2009年 / 52卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S7 / S7

页数：1

共 50 条

[31] One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study
Marco Zavattaro
Marina Caputo
Maria Teresa Samà
Chiara Mele
Luisa Chasseur
Paolo Marzullo
Loredana Pagano
Maria Grazia Mauri
Maria Chantal Ponziani
Gianluca Aimaretti
Flavia Prodam
Endocrine, 2015, 50 : 620 - 626
[32] One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study
Zavattaro, Marco
Caputo, Marina
Sama, Maria Teresa
Mele, Chiara
Chasseur, Luisa
Marzullo, Paolo
Pagano, Loredana
Mauri, Maria Grazia
Ponziani, Maria Chantal
Aimaretti, Gianluca
Prodam, Flavia
ENDOCRINE, 2015, 50 (03) : 620 - 626
[33] EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients
Ryder, Robert E. J.
Yadagiri, Mahi
Burbridge, Wyn
Irwin, Susan P.
Gandhi, Hardeep
Bashir, Tahira
Allden, Rachael A.
Wyres, Melanie
Cull, Melissa
Bleasdale, John P.
Fogden, Edward N.
Anderson, Mark R.
Sen Gupta, Piya
PRACTICAL DIABETES, 2022, 39 (03) : 13 - +
[34] Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
DeFronzo, RA
Ratner, RE
Han, J
Kim, DD
Fineman, MS
Baron, AD
DIABETES CARE, 2005, 28 (05) : 1092 - 1100
[35] Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes
DeFronzo, R
Ratner, R
Han, J
Kim, D
Fineman, M
Baron, A
DIABETOLOGIA, 2004, 47 : A280 - A280
[36] Substantial improvement in β-cell function with initial combination therapy of sitagliptin and metformin in patients with type 2 diabetes after 1 year of treatment
Williams-Herman, Debora
Xu, Lei
Davies, Michael J.
Stein, Peter P.
Amatruda, John M.
DIABETES, 2008, 57 : A161 - A161
[37] Effects of exenatide plus rosiglitazone on measures of beta cell function and insulin sensitivity in subjects with type 2 diabetes previously treated with metformin
Glass, L. C.
Triplitt, C.
Lewis, M. S.
Qu, Y.
Guo, Y.
Maggs, D.
DeFronzo, R. A.
DIABETOLOGIA, 2009, 52 : S286 - S286
[38] A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes
Hanefeld, Markolf
Patwardhan, Rita
Jones, Nigel P.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2007, 17 (01) : 13 - 23
[39] One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes
Taybani, Zoltan J.
Botyik, Balazs
Gyimesi, Andras
Katko, Monika
Varkonyi, Tamas
ENDOCRINOLOGY DIABETES & METABOLISM, 2023, 6 (01)
[40] Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks
Kendall, DM
Kim, D
Poon, T
Han, J
Schnabel, C
Fineman, M
Trautmann, M
Maggs, D
DIABETES, 2005, 54 : A4 - A5

← 1 2 3 4 5 →